Sign In
Buy CATX
$3.56
-0.0400 (-1.11%)
At Close: Jun 03, 2026
SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tre
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results
04:05pm, Tuesday, 12'th Nov 2024
SEATTLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc . (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical compan
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November
07:00am, Tuesday, 29'th Oct 2024
SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tre
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine
07:00am, Wednesday, 23'rd Oct 2024
SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tre
SEATTLE, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced t
SEATTLE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tr
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
05:14pm, Thursday, 10'th Oct 2024
SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced trea
SEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tre
Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept
03:11pm, Wednesday, 02'nd Oct 2024
Perspective Therapeutics, Inc. expects updated data from cohorts 1 & 2 from the phase 1/2a study, using VMT-01 for the treatment of patients with MC1R-positive metastatic melanoma, in the 2nd half of
Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2
12:10pm, Wednesday, 02'nd Oct 2024
Shares of Perspective Therapeutics Inc (CATX, Financial) surged 3.40% in mid-day trading on Oct 2. The stock reached an intraday high of $13.10, before settling at $13.06, up from its previous close o
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine
07:00am, Monday, 30'th Sep 2024
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tr
Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma
07:00am, Thursday, 05'th Sep 2024
SEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tre
Perspective Therapeutics to Participate in Upcoming Investor Conferences in September
07:00am, Wednesday, 28'th Aug 2024
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tre
Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?
10:40am, Tuesday, 13'th Aug 2024
Here is how Perspective Therapeutics (CATX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results
04:05pm, Monday, 12'th Aug 2024
SEATTLE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced trea
